PL1622929T3 - Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie - Google Patents

Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie

Info

Publication number
PL1622929T3
PL1622929T3 PL04760861T PL04760861T PL1622929T3 PL 1622929 T3 PL1622929 T3 PL 1622929T3 PL 04760861 T PL04760861 T PL 04760861T PL 04760861 T PL04760861 T PL 04760861T PL 1622929 T3 PL1622929 T3 PL 1622929T3
Authority
PL
Poland
Prior art keywords
apo2l
trail
receptor binding
binding peptides
apo
Prior art date
Application number
PL04760861T
Other languages
English (en)
Inventor
Bing Li
Sachdev S Sidhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL1622929T3 publication Critical patent/PL1622929T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL04760861T 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie PL1622929T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46943603P 2003-05-09 2003-05-09
EP04760861A EP1622929B1 (en) 2003-05-09 2004-04-29 Apo2l (trail) receptor binding peptides and uses thereof
PCT/US2004/013576 WO2004101608A2 (en) 2003-05-09 2004-04-29 Apo2l (trail) receptor binding peptides and uses thereof

Publications (1)

Publication Number Publication Date
PL1622929T3 true PL1622929T3 (pl) 2007-03-30

Family

ID=33452286

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04760861T PL1622929T3 (pl) 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie
PL06013626T PL1754713T3 (pl) 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L (TRAIL) oraz ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06013626T PL1754713T3 (pl) 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L (TRAIL) oraz ich zastosowanie

Country Status (12)

Country Link
US (1) US20070066800A1 (pl)
EP (2) EP1622929B1 (pl)
JP (1) JP2007530008A (pl)
AT (2) ATE423786T1 (pl)
AU (1) AU2004238794A1 (pl)
CA (1) CA2524456A1 (pl)
DE (2) DE602004002773T2 (pl)
DK (2) DK1622929T3 (pl)
ES (2) ES2322182T3 (pl)
IL (1) IL171733A (pl)
PL (2) PL1622929T3 (pl)
WO (1) WO2004101608A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2009002947A2 (en) * 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN102066403B (zh) * 2009-04-03 2014-10-08 中国医学科学院基础医学研究所 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
DK3389696T3 (da) 2015-12-17 2024-12-16 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
CN116585484B (zh) * 2022-12-13 2023-12-12 广州医科大学 多肽偶联小分子化合物及其抗病毒应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
IL171733A (en) 2010-11-30
DE602004019701D1 (de) 2009-04-09
US20070066800A1 (en) 2007-03-22
JP2007530008A (ja) 2007-11-01
ATE423786T1 (de) 2009-03-15
CA2524456A1 (en) 2004-11-25
DK1622929T3 (da) 2007-02-19
EP1622929A2 (en) 2006-02-08
WO2004101608A2 (en) 2004-11-25
ATE342274T1 (de) 2006-11-15
EP1754713A1 (en) 2007-02-21
DE602004002773D1 (de) 2006-11-23
ES2322182T3 (es) 2009-06-17
DK1754713T3 (da) 2009-06-08
WO2004101608A3 (en) 2004-12-29
ES2274480T3 (es) 2007-05-16
AU2004238794A1 (en) 2004-11-25
DE602004002773T2 (de) 2007-08-16
EP1622929B1 (en) 2006-10-11
PL1754713T3 (pl) 2009-07-31
EP1754713B1 (en) 2009-02-25

Similar Documents

Publication Publication Date Title
IL158920A0 (en) Taci-immunoglobulin fusion proteins
IL161016A (en) Polypeptides capable of ang-2 binding
EP2270040A3 (en) Binding polypeptides for B lymphocyte stimulator protein (BLyS)
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
IL210392A0 (en) Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
AU2003209272A1 (en) Engineered binding proteins
IL171733A (en) Apo2l (trail) receptor binding peptides and uses thereof
WO2007079218A3 (en) Metalloproteinase binding proteins
WO2004013290A3 (en) Compositions and methods for molecular biology
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
WO2002062957A3 (en) Ter sites and ter binding proteins
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
AU2003261102A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
WO2009047474A3 (en) Modified growth hormone polypeptides
WO2003100379A3 (en) Methods and reagents for removing contaminants from biomolecules
HK1088255A (en) Antibodies and fusion proteins that include engineered constant regions